MONTREAL, Aug. 9 /CNW Telbec/ - Primolio Sales Inc. ("Primolio") and
Valco Enterprises LLP are pleased to announce that they have entered into
asset purchase agreements dated as of August 1st, 2007 with a wholly-owned
subsidiary of Arura Pharma Inc. (TSX-V: ARP) ("Arura") to sell assets related
to the Neolia Brand, including the world-wide rights in the Neolia Brands
family of trademarks (collectively the "Assets"). The aggregate purchase price
for the Assets was USD$6,800,000 (excluding inventory), of which USD$3,400,000
was ultimately paid by Arura by issuing to Primolio an aggregate of
23,747,160 common shares of Arura at a deemed issuance price of CDN$0.15 per
Arura common share (the "Acquisition").
As a result of the closing of the Acquisition, Primolio has received
23,747,160 common shares in the capital of Arura, which represent
approximately 24% of the outstanding common shares of Arura. A copy of the
early warning report filed pursuant to the applicable securities legislation
is available online at www.sedar.com under Arura's profile or may be obtained
by contacting Mr. Claus Brueckner.
Cautionary Statement on Forward-Looking Information
The statements made in this News Release may contain certain
forward-looking statements. Actual events or results may differ from
expectations. Certain risk factors may also affect the actual results achieved
by the Company.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Mr. Claus Brueckner, (514) 938-8474, Fax: (514)